Haemonetics (HAE) reported $321.39 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 4.4%. EPS of $1.10 for the same period compares to $1.02 a year ago.
The reported revenue represents a surprise of +5.97% over the Zacks Consensus Estimate of $303.28 million. With the consensus EPS estimate being $1.01, the EPS surprise was +8.91%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Haemonetics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net revenues- Plasma: $129.9 million versus $113.65 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -4.4% change.
- Net revenues- Hospital: $139.66 million versus the three-analyst average estimate of $144.4 million. The reported number represents a year-over-year change of +4.2%.
- Net revenues- Blood Center: $51.84 million versus $46.38 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -21.8% change.
View all Key Company Metrics for Haemonetics here>>>
Shares of Haemonetics have returned -2.3% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Haemonetics Corporation (HAE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
